Improving Affordability in Dermatology: Cost Savings in Mark Cuban Cost Plus Drug Company Versus GoodRx
AbstractThis observational cost analysis was conducted to assess the efficacy of the Mark Cuban Cost Plus Drug Company (CostPlus) relative to GoodRx and found that CostPlus has significant potential to improve the financial burden of prescription medications within dermatology.
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2024-12-01
|
| Series: | JMIR Dermatology |
| Online Access: | https://derma.jmir.org/2024/1/e64300 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846114054299451392 |
|---|---|
| author | Christopher G Youn Joo Yeon Kim Vivian B Yang Gordon H Bae |
| author_facet | Christopher G Youn Joo Yeon Kim Vivian B Yang Gordon H Bae |
| author_sort | Christopher G Youn |
| collection | DOAJ |
| description |
AbstractThis observational cost analysis was conducted to assess the efficacy of the Mark Cuban Cost Plus Drug Company (CostPlus) relative to GoodRx and found that CostPlus has significant potential to improve the financial burden of prescription medications within dermatology. |
| format | Article |
| id | doaj-art-f54af4328f424382a71a9b0452a755a4 |
| institution | Kabale University |
| issn | 2562-0959 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIR Dermatology |
| spelling | doaj-art-f54af4328f424382a71a9b0452a755a42024-12-20T21:17:49ZengJMIR PublicationsJMIR Dermatology2562-09592024-12-017e64300e6430010.2196/64300Improving Affordability in Dermatology: Cost Savings in Mark Cuban Cost Plus Drug Company Versus GoodRxChristopher G Younhttp://orcid.org/0000-0002-1873-7655Joo Yeon Kimhttp://orcid.org/0000-0001-5899-8238Vivian B Yanghttp://orcid.org/0000-0001-9302-0403Gordon H Baehttp://orcid.org/0000-0001-9996-4763 AbstractThis observational cost analysis was conducted to assess the efficacy of the Mark Cuban Cost Plus Drug Company (CostPlus) relative to GoodRx and found that CostPlus has significant potential to improve the financial burden of prescription medications within dermatology.https://derma.jmir.org/2024/1/e64300 |
| spellingShingle | Christopher G Youn Joo Yeon Kim Vivian B Yang Gordon H Bae Improving Affordability in Dermatology: Cost Savings in Mark Cuban Cost Plus Drug Company Versus GoodRx JMIR Dermatology |
| title | Improving Affordability in Dermatology: Cost Savings in Mark Cuban Cost Plus Drug Company Versus GoodRx |
| title_full | Improving Affordability in Dermatology: Cost Savings in Mark Cuban Cost Plus Drug Company Versus GoodRx |
| title_fullStr | Improving Affordability in Dermatology: Cost Savings in Mark Cuban Cost Plus Drug Company Versus GoodRx |
| title_full_unstemmed | Improving Affordability in Dermatology: Cost Savings in Mark Cuban Cost Plus Drug Company Versus GoodRx |
| title_short | Improving Affordability in Dermatology: Cost Savings in Mark Cuban Cost Plus Drug Company Versus GoodRx |
| title_sort | improving affordability in dermatology cost savings in mark cuban cost plus drug company versus goodrx |
| url | https://derma.jmir.org/2024/1/e64300 |
| work_keys_str_mv | AT christophergyoun improvingaffordabilityindermatologycostsavingsinmarkcubancostplusdrugcompanyversusgoodrx AT jooyeonkim improvingaffordabilityindermatologycostsavingsinmarkcubancostplusdrugcompanyversusgoodrx AT vivianbyang improvingaffordabilityindermatologycostsavingsinmarkcubancostplusdrugcompanyversusgoodrx AT gordonhbae improvingaffordabilityindermatologycostsavingsinmarkcubancostplusdrugcompanyversusgoodrx |